Leerink says Amgen disclosed “underwhelming” Phase 3 data for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis in an investor call. Both therapies appear less efficacious than competing, approved products in their respective indications, the analyst tells investors in a research note. For rocatinlimab, the firm also highlights that Amgen did not disclose detailed safety data. It believes docatinlimab efficacy “appears weak” versus Dupixent while safety “is a question mark.” Amgen in early trading is down 4%, or $13.16, to $317.76. Leerink has a Market Perform rating on the name.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen’s (AMGN) Drugs Show Promise in Phase 3 Trials
- Amgen announces approval of TEPEZZA to treat CAS or TED in Japan
- Regeneron price target lowered to $1,252 from $1,282 at RBC Capital
- Regeneron weakness to Amgen injuction ruling an ‘overreaction’, says Truist
- Leerink cuts Regeneron to Market Perform on Eylea franchise outlook uncertainty